Skip to main content
Clinical Trials/NCT02228824
NCT02228824
Completed
Not Applicable

The Effect of Very-Low Nicotine Cigarettes on Smoking in Non-Daily Smokers

Saul Shiffman1 site in 1 country312 target enrollmentJune 2015

Overview

Phase
Not Applicable
Intervention
Very low nicotine content cigarettes
Conditions
Smoking
Sponsor
Saul Shiffman
Enrollment
312
Locations
1
Primary Endpoint
Change in Cigarette Consumption
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this research study is to investigate the impact of different nicotine levels in cigarettes among non-daily smokers. This research may help inform the Food and Drug Administration (FDA) on how best to regulate tobacco products in the future, with the goal of improving public health.

Detailed Description

The overall goal of the study is to assess the effects of switching to Very-Low-Nicotine-Content cigarettes (VLNCCs) among non-daily, or intermittent smokers (ITS). This is a two-arm randomized study with an own-cigarette baseline control. After a 2-week baseline period smoking their own cigarettes, 455 ITS will be randomized (double-blind) for 10 weeks to smoke experimental cigarettes, either: (a) normal nicotine content cigarettes (NNCCs; 0.8 mg) or (b) VLNCCs (0.07 mg), each matched to menthol status of subjects' preferred brand. ITS are more likely to be African-American (AA) smokers; thus AA smokers will be oversampled (to one third of the total sample). Change in cigarette consumption is the primary end-point, and biomarkers of smoke exposure and measures of smoking intensity are also assessed.

Registry
clinicaltrials.gov
Start Date
June 2015
End Date
July 31, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Saul Shiffman
Responsible Party
Sponsor Investigator
Principal Investigator

Saul Shiffman

Research Professor

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • age 18 years or older, and smoking cigarettes for at least 3 years
  • smoking, on average, 4-27 days per month
  • smoking at current rate for at least the previous 3 months
  • willingness to try novel cigarettes

Exclusion Criteria

  • active plans to quit or actively seeking smoking cessation treatment in the next 3 months
  • severe psychiatric disorders that may interfere with study procedures
  • current, regular (i.e., monthly or more) use of nicotine replacement or other tobacco products, by self-report
  • exclusive use of roll-your-own cigarettes (since the study uses manufactured cigarettes)
  • \[for female participants\] being pregnant or breastfeeding, or planning to become pregnant, by self-report
  • current use of medications such as Chantix (varenicline), Zyban, Wellbutrin, or bupropion for any purpose, including stopping smoking
  • occurrence of heart attack, stroke, or angina in the past 3 months

Arms & Interventions

Very low nicotine content cigarettes

Intervention: Very low nicotine content cigarettes

Normal nicotine content cigarettes

Intervention: Normal nicotine content cigarettes

Outcomes

Primary Outcomes

Change in Cigarette Consumption

Time Frame: Two-week pre-intervention baseline period compared to final two weeks of 10-week intervention period

Difference in mean daily cigarette consumption between initial two-week baseline period and final two weeks of experimental period, using imputed data

Secondary Outcomes

  • Exposure Measure - Solanesol(Post-randomization time points at study weeks 4, 8, 12)
  • Exposure Measure - Smoking Topography(Post-randomization study visits at study weeks 4, 8, 12)
  • Exposure Measure - Cotinine (Logged)(Post-randomization office visits weeks 2 (end of baseline period) and 12 (end of study))
  • Exposure Measure - Cigarette Butt Weight(Entire length of study, through completion, up to 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials